American Journal of Psychiatry · 2011 · 225 citations · 21 references
MedicinePharmacologyPharmacotherapyAutism Spectrum DisordersNeuropharmacologyPsychopharmacologyNeurodevelopmental DisordersObsessive-compulsive DisordersRepetitive BehaviorsAutism Spectrum Disorder InterventionAutism Spectrum TraitsBehavioral Outcome AssessmentDouble-blind TrialsObsessive-compulsive Disorder TreatmentPlacebo ComparatorsRepetitive Behavior Assessment
OBJECTIVE: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). METHOD: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day. Repetitive behaviors were measured with the compulsion subscale of the Yale-Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. RESULTS: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. CONCLUSIONS: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.
21
Catherine Lord, Michael Rutter, Ann Le Couteur · Journal of Autism and Developmental Disorders · 1994 · 9.1K citations
Education, Psychiatry, Psychology +13
The Yale-Brown Obsessive Compulsive Scale
Wayne K. Goodman · Archives of General Psychiatry · 1989 · 7.6K citations
Catherine Lord, Susan Risi, Linda Lambrecht et al. · Journal of Autism and Developmental Disorders · 2000 · 7.6K citations
Adult outcome for children with autism
Patricia Howlin, Susan Goode, Jane Hutton et al. · Journal of Child Psychology and Psychiatry · 2004 · 1.8K citations
Autism From 2 to 9 Years of Age
Catherine Lord, Susan Risi, Pamela S. DiLavore et al. · Archives of General Psychiatry · 2006 · 975 citations · Full text